253 related articles for article (PubMed ID: 26905326)
1. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
[TBL] [Abstract][Full Text] [Related]
2. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P
J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897
[TBL] [Abstract][Full Text] [Related]
3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
4. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
8. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitor pick-me-up.
Mullard A
Nat Rev Drug Discov; 2019 Oct; 18(11):814. PubMed ID: 31673138
[No Abstract] [Full Text] [Related]
11. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory PARP w terapii raka jajnika.
Kruczała MA; Grela-Wojewoda A; Cedrych I
Ginekol Pol; 2016; 87(2):131-4. PubMed ID: 27306290
[TBL] [Abstract][Full Text] [Related]
14. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
[TBL] [Abstract][Full Text] [Related]
15. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
16. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
17. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
Chelariu-Raicu A; Zibetti Dal Molin G; Coleman RL
Int J Gynecol Cancer; 2020 Oct; 30(10):1608-1618. PubMed ID: 32928926
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors for anticancer therapy.
Curtin N
Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
